Liana F. Van der Gang

Liana F. Van der Gang

Auto-generated profile, based on publicly available information

Liana F. Van der Gang

Department of Dermatology and Allergology, National Expertise Center for Atopic Dermatitis, University Medical Center Utrecht, Utrecht, The Netherlands

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 April 2025 in Journal of the European Academy of Dermatology and Venereology
Verified
Journal Article
Open access
LGLian F. van der Gang
Lian F. van der Gang
KAKeneshka Atash
Keneshka Atash
NZNicolaas P. A. Zuithoff
Nicolaas P. A. Zuithoff
IHInge Haeck
Inge Haeck
CBCeleste M. Boesjes
Celeste M. Boesjes
MBMarjolein S. de Bruin‐Weller
Marjolein S. de Bruin‐Weller
Background: Limited data exist on the comparative risk of infections during biologic and Janus kinase inhibitor (JAKi) treatment for atopic dermatitis (AD) in daily practice. Objectives: To assess the differential infection risk of biologic and JAKi treatment in patients with moderate‐to‐severe AD in a real‐world setting. Methods: This prospective, multicentre study evaluated treatment‐emergent infections in patients (age ≥ 12 years) using biologics or JAKi from the BioDay registry from October 2017 to July 2024. Crude incidence rates were calculated per 100 patient‐years (PY) per treatment. Cox regression for recurrent events, adjusted for potential confounders, was used to estimate hazard ratios (HR) for the rate of infections, with subgroup and sensitivity analyses in bio‐/JAKi‐naïve patients. Results: In total 1793 patients were included (4044.1 PY; 1886 biologic treatment episodes (TEs); 480 JAKi), with 794 infections. JAKi showed higher infection rates (58.4–65.5/100 PY) compared to biologics (13.6–22.0), especially for herpes infections ( n = 195, 24.6%; JAKi 13.6–19.8 vs. biologicals 3.0–3.6). Cox regression indicated increased rates with JAKi (abrocitinib HR 4.1, 95% CI: 3.1–5.5; baricitinib HR 4.2, 95% CI: 2.9–6.2; upadacitinib HR 4.0, 95% CI: 3.2–5.0; all p < 0.0001) and a slight increase with tralokinumab (HR 1.4, 95% CI: 1.0–2.0, p = 0.039) compared to dupilumab. Sensitivity analyses confirmed these results, except for tralokinumab. Rates of severe infections were higher with JAKi compared to dupilumab, although absolute numbers were low and associations were not consistently significant. History of infection, predominantly viral or fungal skin infections (HR 1.9, 95% CI: 1.4–2.6, p < 0.0001; 2.4, 1.3–4.4, p = 0.003, resp.), was identified as an independent factor associated with infection. Conclusions: This cohort study demonstrated an increased risk of infection during JAKi treatment compared to dupilumab for moderate‐to‐severe AD. These findings enhance understanding of the differential infection risk with targeted therapies in AD, aiding tailored treatment choices that consider patient‐specific risks such as prior skin infections.

16 February 2023 in Acta Dermato-Venereologica
Verified
Journal Article
Open access
PDF file
CBCeleste M. Boesjes
Celeste M. Boesjes
LGLiana F. Van der Gang
Liana F. Van der Gang
NZNicolaas P.A. Zuithoff
Nicolaas P.A. Zuithoff
DBDaphne S. Bakker
Daphne S. Bakker
LSLotte S. Spekhorst
Lotte S. Spekhorst
MBMarjolein S. De Bruin-Weller
Marjolein S. De Bruin-Weller
Clinical trials showed that upadacitinib, a selective Janus kinase-1 inhibitor, is effective for treatment of moderate-to-severe atopic dermatitis. However, daily practice studies are limited. This multicentre prospective study evaluated the effectiveness of 16 weeks of upadacitinib treatment for moderate-to-severe atopic dermatitis in adult patients, including those with previous inadequate response to dupilumab and/or baricitinib, in daily practice. A total of 47 patients from the Dutch BioDay registry treated with upadacitinib were included. Patients were evaluated at baseline, and after 4, 8 and 16 weeks of treatment. Effectiveness was assessed by clinician- and patient-reported outcome measurements. Safety was assessed by adverse events and laboratory assessments. Overall, the probabilities (95% confidence intervals) of achieving Eczema Area and Severity Index ≤ 7 and Numerical Rating Scale – pruritus ≤ 4 were 73.0% (53.7–86.3) and 69.4% (48.7–84.4), respectively. The effectiveness of upadacitinib was comparable in patients with inadequate response to dupilumab and/or baricitinib and in patients who were naïve for these treatments or who had stopped such treatments due to adverse events. Fourteen (29.8%) patients discontinued upadacitinib due to ineffectiveness, adverse events or both (8.5%, 14.9% and 6.4%, respectively). Most frequently reported adverse events were acneiform eruptions (n = 10, 21.3%), herpes simplex (n = 6, 12.8%), nausea and airway infections (both n = 4, 8.5%). In conclusion, upadacitinib is an effective treatment for patients with moderate-to-severe atopic dermatitis, including those with previous inadequate response to dupilumab and/or baricitinib treatment.

24 January 2025 in ImmunoHorizons
Verified
Journal Article
Open access
STSara M Tamminga
Sara M Tamminga
MWM Marlot Van Der Wal
M Marlot Van Der Wal
ESElise S Saager
Elise S Saager
LGLian F Van Der Gang
Lian F Van Der Gang
CBCeleste M Boesjes
Celeste M Boesjes
NSNina M. van Sorge
Nina M. van Sorge
Atopic dermatitis (AD) is characterized by dysregulated T cell immunity and skin microbiome dysbiosis with predominance of Staphylococcus aureus, which is associated with exacerbating AD skin inflammation. Specific glycosylation patterns of S. aureus cell wall structures amplify skin inflammation through interaction with Langerhans cells (LCs). Nevertheless, the role of LCs in AD remains poorly characterized. Here, we performed single cell RNA sequencing of primary epidermal LCs and dermal T cells, isolated from skin biopsies of AD patients and healthy control subjects, alongside specific glycoanalysis of S. aureus strains isolated from the AD lesions. Our findings revealed 4 LC subpopulations ie, 2 steady-state clusters [LC1 and LC1H] and 2 proinflammatory/matured subsets [LC2 and migratory LCs]. The latter 2 subsets were enriched in AD skin. AD LCs showed enhanced expression of C-type lectin receptors, the high-affinity IgE receptor, and activation of prostaglandin and leukotriene biosynthesis pathways, upregulated transcriptional signatures related to T cell activation pathways, and increased expression of CCL17 compared with healthy LCs. Correspondingly, T helper 2 and T regulatory cell populations were increased in AD lesions. Complementary, we performed bulk RNA sequencing of primary LCs stimulated with the S. aureus strains isolated from the AD lesions, which showed upregulation of T helper 2–related pathways. Our study provides proof-of-concept for a role of LCs in connecting the S. aureus–T cell axis in the AD inflammatory cycle.

9 December 2025 in Allergy
Verified
Journal Article
Open access
LGLian F. van der Gang
Lian F. van der Gang
CBCeleste M. Boesjes
Celeste M. Boesjes
NZNicolaas P. A. Zuithoff
Nicolaas P. A. Zuithoff
IHInge Haeck
Inge Haeck
OBOctavian Bacoş‐Cosma
Octavian Bacoş‐Cosma
MBMarjolein S. de Bruin‐Weller
Marjolein S. de Bruin‐Weller

4 February 2025 in Clinical & Experimental Allergy
Verified
Journal Article
Open access
CBCeleste M. Boesjes
Celeste M. Boesjes
LGLian F. van der Gang
Lian F. van der Gang
DBDaphne S. Bakker
Daphne S. Bakker
CJC. F. Den Hartog Jager
C. F. Den Hartog Jager
MGMarlies de Graaf
Marlies de Graaf
EKEdward F. Knol
Edward F. Knol

13 April 2026 in Journal of the European Academy of Dermatology and Venereology
Verified
Journal Article
Open access
LGLian F. van der Gang
Lian F. van der Gang
NZNicolaas P. A. Zuithoff
Nicolaas P. A. Zuithoff
IHInge M. Haeck
Inge M. Haeck
VHVeroniek E. M. Harbers
Veroniek E. M. Harbers
SSSimone Stadhouders‐Keet
Simone Stadhouders‐Keet
MGMarlies de Graaf
Marlies de Graaf
Background: Dupilumab and tralokinumab for atopic dermatitis (AD) target the type 2 axis through different mechanisms of action, which may lead to variation in effectiveness and safety. Head‐to‐head trials, however, are lacking. Objectives: To compare the real‐world effectiveness and safety of dupilumab and tralokinumab in AD. Methods: This prospective cohort study enrolled biologic−/Janus kinase inhibitor‐naïve AD patients (≥12 years) from the BioDay registry who initiated dupilumab or tralokinumab between November 2021 and September 2024. Visits were scheduled at baseline, 4 weeks and every 3 months up to 52 weeks. Effectiveness outcomes included Eczema Area and Severity Index (EASI), weekly mean pruritus Numeric Rating Scale (NRS), treat‐to‐target thresholds (EASI ≤ 7; NRS‐pruritus ≤ 4, with patients discontinuing treatment considered non‐responders) and drug survival. Adverse events (AEs) were assessed at each visit. Inverse probability of treatment weighting (IPTW) was used to balance treatment groups. Results: In total, 750 patients were included (643 dupilumab; 107 tralokinumab). After IPTW, baseline characteristics were well balanced. During follow‐up, dupilumab patients had lower EASI scores than tralokinumab patients, although differences were not consistently statistically significant ( p = 0.10). NRS‐pruritus scores were significantly lower with dupilumab at all visits ( p < 0.0001), mean differences did not exceed the 2‐point clinical relevance threshold. The probability of achieving EASI ≤ 7 and NRS‐pruritus ≤ 4 was higher with dupilumab (both p < 0.0001), with risk differences of 34.7% and 40.2% at 52 weeks, respectively. After 52 weeks, dupilumab drug survival was 92.6% vs. 70.6% for tralokinumab. Ocular surface disease incidence was similar (HR 1.0, 95% CI 0.6–1.6, p = 0.94) between treatments, leading to discontinuation of dupilumab in n = 23 (3.4/100 PY) and tralokinumab in n = 5 (5.4/100 PY). Conclusions: In this real‐world comparison, dupilumab provided superior effectiveness compared with tralokinumab. In responders continuing treatment, EASI and NRS‐pruritus differences were small. More substantial differences were observed when treatment targets EASI ≤ 7 and NRS‐pruritus ≤ 4, and discontinuation rates were taken into account.